Aptamer Diagnostics specialises in the development, modification and integration of aptamers into a wide variety of diagnostic and detection platforms like ELISA-like assays, Lateral Flow Devices, Biosensors, Cell and Tissue Imaging and Aptamer Beacons.
Aptamers are ideal for customers who wish to diversify their product portfolio, develop new lines of products, develop diagnostic kits with standardised reagents, extended shelf-life, or remove the need for cold chain supply.
We have adapted commonly used diagnostic platforms to incorporate aptamers into familiar formats. The benefits of the aptamer selection process mean that these assays can be made available for targets previously seen as difficult for these assays.
For special applications, our experienced R&D team works hand-in-hand with you to develop new diagnostic assays ensuring that our aptamers will perform best in your real world application.
Antibodies were unable to discriminate between the active form of a chemotherapeutic and its metabolites. Assay development was further complicated by high background signals from non-specific interactions with plasma.
Highly specific aptamers were selected against the chemotherapeutic agent. Counter-selection steps were included to ensure that the aptamers discriminated between the active drug and its metabolites. Plasma was included during aptamer selections to ensure that the aptamers function in human plasma.
The resulting aptamers show excellent discrimination and a linear concentration dependent response spanning the therapeutic concentration range.